AGRX News and Press, Agile Therapeutics Inc. From 10/26/22

(NewsDirect) From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth contro...

--News Direct-- From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth con...

--News Direct-- Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/ View original content to download multimedia: https://newsdirect.c...

Agile Therapeutics ( NASDAQ: AGRX ) said on Oct. 7 that it appointed Amy Welsh as chief commercial officer, effective Nov. 1, as part of a reorganization of its leadership team to to promote birth control patch Twirla (levonorgestrel and ethinyl estradiol). ...

Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla ® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- ...

The following slide deck was published by Agile Therapeutics, Inc. in conjunction with this event. For further details see: Agile Therapeutics (AGRX) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow

PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24 th Annual Glob...

Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q2 2022 Earnings Call Transcript

Agile Therapeutics, Inc. (AGRX) Q2 2022 Results Conference Call August 11, 2022 04:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing Conference Call Participants Oren Livnat - H.C. Wainright ...

Agile Therapeutics press release ( NASDAQ: AGRX ): Q2 GAAP EPS of -$2.71 beats by $0.99 . Revenue of $2.1M (+75.0% Y/Y) beats by $0.12M . “Our goals as a company are to grow our Twirla brand and become cash flow positive. We believe we took important ste...